{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T20:05:54Z","timestamp":1795205154398,"version":"4.10.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010067","name":"Gobierno de Arag\u00f3n","doi-asserted-by":"publisher","award":["B49_23R"],"award-info":[{"award-number":["B49_23R"]}],"id":[{"id":"10.13039\/501100010067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010067","name":"Gobierno de Arag\u00f3n","doi-asserted-by":"publisher","award":["PhD contract order IIU\/796\/2019"],"award-info":[{"award-number":["PhD contract order IIU\/796\/2019"]}],"id":[{"id":"10.13039\/501100010067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Ministry of Economy and Competitiveness | Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019-106859GA-I00"],"award-info":[{"award-number":["PID2019-106859GA-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Ministry of Economy and Competitiveness | Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-115800GB-I00"],"award-info":[{"award-number":["PID2020-115800GB-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010784","name":"Banco Santander","doi-asserted-by":"publisher","award":["Santander-UZ 2020\/0274"],"award-info":[{"award-number":["Santander-UZ 2020\/0274"]}],"id":[{"id":"10.13039\/100010784","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Soremartec S.A. and Soremartec Italia, Ferrero Group."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In tuberculosis (TB) vaccine development, multiple factors hinder the design and interpretation of the clinical trials used to estimate vaccine efficacy. The complex transmission chain of TB includes multiple routes to disease, making it hard to link the vaccine efficacy observed in a trial to specific protective mechanisms. Here, we present a Bayesian framework to evaluate the compatibility of different vaccine descriptions with clinical trial outcomes, unlocking impact forecasting from vaccines whose specific mechanisms of action are unknown. Applying our method to the analysis of the M72\/AS01<jats:sub>E<\/jats:sub> vaccine trial -conducted on IGRA+ individuals- as a case study, we found that most plausible models for this vaccine needed to include protection against, at least, two over the three possible routes to active TB classically considered in the literature: namely, primary TB, latent TB reactivation and TB upon re-infection. Gathering new data regarding the impact of TB vaccines in various epidemiological settings would be instrumental to improve our model estimates of the underlying mechanisms.<\/jats:p>","DOI":"10.1038\/s41467-023-40976-6","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T09:02:56Z","timestamp":1693558976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Addressing mechanism bias in model-based impact forecasts of new tuberculosis vaccines"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-3650","authenticated-orcid":false,"given":"M.","family":"Tovar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-1893","authenticated-orcid":false,"given":"Y.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-9685","authenticated-orcid":false,"given":"J.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"40976_CR1","first-page":"115","volume":"14","author":"A Kazemnejad","year":"2014","unstructured":"Kazemnejad, A., Arsang Jang, S., Amani, F. & Omidi, A. Global epidemic trend of tuberculosis during 1990-2010: using segmented regression model. J. Res. Health Sci. 14, 115\u201321 (2014).","journal-title":"J. Res. Health Sci."},{"key":"40976_CR2","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","volume":"385","author":"M Uplekar","year":"2015","unstructured":"Uplekar, M. et al. WHO\u2019s new end TB strategy. Lancet 385, 1799\u2013801. (2015).","journal-title":"Lancet"},{"key":"40976_CR3","unstructured":"World Health Organization. (2022). Global Tuberculosis Report 2021."},{"key":"40976_CR4","doi-asserted-by":"publisher","first-page":"100603","DOI":"10.1016\/j.eclinm.2020.100603","volume":"28","author":"L Cilloni","year":"2020","unstructured":"Cilloni, L. et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinical Medicine 28, 100603 (2020).","journal-title":"EClinical Medicine"},{"key":"40976_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/resp.13304","volume":"23","author":"C Lange","year":"2018","unstructured":"Lange, C. et al. Drug-resistant tuberculosis: an update on disease burden, diagnosis and treatment. Respirology 23, 656\u201373 (2018).","journal-title":"Respirology"},{"key":"40976_CR6","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.12688\/f1000research.16521.1","volume":"7","author":"LK Schrager","year":"2018","unstructured":"Schrager, L. K., Harris, R. C. & Vekemans, J. Research and development of new tuberculosis vaccines: a review. F1000Res. 7, 1732 (2018).","journal-title":"F1000Res."},{"key":"40976_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/003655401753382576","volume":"33","author":"PEM Fine","year":"2001","unstructured":"Fine, P. E. M. BCG: the challenge continues. Scand. J. Infect. Dis. 33, 58\u201360 (2001).","journal-title":"Scand. J. Infect. Dis."},{"key":"40976_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021\u20138 (2013).","journal-title":"Lancet"},{"key":"40976_CR9","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379","author":"O Van Der Meeren","year":"2018","unstructured":"Van Der Meeren, O. et al. Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis. N. Engl. J. Med. 379, 1621\u201334 (2018).","journal-title":"N. Engl. J. Med."},{"key":"40976_CR10","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","volume":"381","author":"DR Tait","year":"2019","unstructured":"Tait, D. R. et al. Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis. N. Engl. J. Med. 381, 2429\u20132439 (2019).","journal-title":"N. Engl. J. Med."},{"key":"40976_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1128\/CVI.00721-14","volume":"22","author":"K Bhatt","year":"2015","unstructured":"Bhatt, K., Verma, S., Ellner, J. J. & Salgame, P. Quest for correlates of protection against tuberculosis. Clin. Vaccine Immunol. 22, 258\u201366 (2015).","journal-title":"Clin. Vaccine Immunol."},{"key":"40976_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S2213-2600(19)30274-7","volume":"7","author":"H McShane","year":"2019","unstructured":"McShane, H. Insights and challenges in tuberculosis vaccine development. Lancet Respir. Med. 7, 810\u20139 (2019).","journal-title":"Lancet Respir. Med."},{"key":"40976_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes, E. et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N. Engl. J. Med. 379, 138\u201349 (2018).","journal-title":"N. Engl. J. Med."},{"key":"40976_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tube.2015.02.036","volume":"95","author":"RD Ellis","year":"2015","unstructured":"Ellis, R. D. et al. Innovative clinical trial designs to rationalize TB vaccine development. Tuberculosis 95, 352\u20137 (2015).","journal-title":"Tuberculosis"},{"key":"40976_CR15","unstructured":"Frick, M. 2016 report on tuberculosis research funding trends, 2005\u20132015: no time to lose. Treatment Action Group (2016)."},{"key":"40976_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-13387-9","volume":"10","author":"M Tovar","year":"2019","unstructured":"Tovar, M. et al. Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines. Nature Commun. 10, 1\u201310 (2019).","journal-title":"Nature Commun."},{"key":"40976_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/joim.13197","volume":"288","author":"CK Weerasuriya","year":"2020","unstructured":"Weerasuriya, C. K., Clark, R. A., White, R. G. & Harris, R. C. New tuberculosis vaccines: advances in clinical development and modelling. J. Int. Med. 288, 661\u201381 (2020).","journal-title":"J. Int. Med."},{"key":"40976_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ije\/13.1.87","volume":"13","author":"PG Smith","year":"1984","unstructured":"Smith, P. G., Rodrigues, L. C. & Fine, P. E. M. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int. J. Epidemiol. 13, 87\u201393 (1984).","journal-title":"Int. J. Epidemiol."},{"key":"40976_CR19","doi-asserted-by":"publisher","first-page":"e1003849","DOI":"10.1371\/journal.ppat.1003849","volume":"10","author":"MGM Gomes","year":"2014","unstructured":"Gomes, M. G. M. et al. A missing dimension in measures of vaccination impacts. PLOS Pathogens 10, e1003849 (2014).","journal-title":"PLOS Pathogens"},{"key":"40976_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijmyco.2016.09.017","volume":"5","author":"P-J Cardona","year":"2016","unstructured":"Cardona, P.-J. Reactivation or reinfection in adult tuberculosis: is that the question? Int. J. Mycobacteriol. 5, 400\u2013407 (2016).","journal-title":"Int. J. Mycobacteriol."},{"key":"40976_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/S0950268897007917","volume":"119","author":"E Vynnycky","year":"1997","unstructured":"Vynnycky, E. & Fine, P. E. M. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect. 119, 183\u2013201 (1997).","journal-title":"Epidemiol. Infect."},{"key":"40976_CR22","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/S1473-3099(18)30134-8","volume":"18","author":"NA Menzies","year":"2018","unstructured":"Menzies, N. A. et al. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infect. Dis. 18, e228\u2013e238 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"40976_CR23","doi-asserted-by":"publisher","first-page":"E3238","DOI":"10.1073\/pnas.1720606115","volume":"115","author":"S Arregui","year":"2018","unstructured":"Arregui, S. et al. Data-driven model for the assessment of Mycobacterium tuberculosis transmission in evolving demographic structures. Proc. Natl. Acad. Sci. 115, E3238\u2013E3245 (2018).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"40976_CR24","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/S2214-109X(18)30452-2","volume":"7","author":"RC Harris","year":"2019","unstructured":"Harris, R. C. et al. Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study. Lancet Glob Health 7, e209\u2013e218 (2019).","journal-title":"Lancet Glob Health"},{"key":"40976_CR25","doi-asserted-by":"publisher","first-page":"eaax4607","DOI":"10.1126\/scitranslmed.aax4607","volume":"12","author":"RC Harris","year":"2020","unstructured":"Harris, R. C., Sumner, T., Knight, G. M., Zhang, H. & White, R. G. Potential impact of tuberculosis vaccines in China, South Africa, and India. Sci. Transl. Med. 12, eaax4607 (2020).","journal-title":"Sci. Transl. Med."},{"key":"40976_CR26","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/S1473-3099(22)00153-0","volume":"22","author":"DW Dowdy","year":"2022","unstructured":"Dowdy, D. W. & Behr, M. A. Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings? Lancet Infect. Dis. 22, e271\u2013e278 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"40976_CR27","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1164\/rccm.202007-2686OC","volume":"203","author":"CAM Mpande","year":"2021","unstructured":"Mpande, C. A. M. et al. Antigen-specific T-cell activation distinguishes between recent and remote tuberculosis infection. Am. J. Respir. Crit. Care Med. 203, 1556\u20131565 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"40976_CR28","doi-asserted-by":"publisher","first-page":"13980","DOI":"10.1073\/pnas.0901720106","volume":"106","author":"LJ Abu-Raddad","year":"2009","unstructured":"Abu-Raddad, L. J. et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad Sci. 106, 13980\u201313985 (2009).","journal-title":"Proc. Natl Acad Sci."},{"key":"40976_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0025-5564(02)00133-5","volume":"180","author":"BM Murphy","year":"2002","unstructured":"Murphy, B. M., Singer, B. H., Anderson, S. & Kirschner, D. Comparing epidemic tuberculosis in demographically distinct heterogeneous populations. Math. Biosci. 180, 161\u2013185 (2002).","journal-title":"Math. Biosci."},{"key":"40976_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0022-5193(03)00038-9","volume":"223","author":"BM Murphy","year":"2003","unstructured":"Murphy, B. M., Singer, B. H. & Kirschner, D. On treatment of tuberculosis in heterogeneous populations. J. Theor. Biol. 223, 391\u2013404 (2003).","journal-title":"J. Theor. Biol."},{"key":"40976_CR31","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/S1473-3099(20)30728-3","volume":"21","author":"KD Dale","year":"2021","unstructured":"Dale, K. D. et al. Quantifying the rates of late reactivation tuberculosis: a systematic review. Lancet Infect. Dis. 21, e303\u2013e317 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"40976_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/cid\/cir951","volume":"54","author":"JR Andrews","year":"2012","unstructured":"Andrews, J. R. et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis 54, 784\u2013791 (2012).","journal-title":"Clin. Infect. Dis"},{"key":"40976_CR33","first-page":"8","volume":"125","author":"GW Comstock","year":"1982","unstructured":"Comstock, G. W. Epidemiology of tuberculosis. Am. Rev. Respir. Dis. 125, 8\u201315 (1982).","journal-title":"Am. Rev. Respir. Dis."},{"key":"40976_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0041-3879(82)80013-5","volume":"63","author":"I Sutherland","year":"1982","unstructured":"Sutherland, I., Svandova, E. & Radhakrishna, S. The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 63, 255\u2013268 (1982).","journal-title":"Tubercle"},{"key":"40976_CR35","unstructured":"WHO tuberculosis database: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/data."},{"key":"40976_CR36","unstructured":"UN population division database: https:\/\/population.un.org\/wpp\/."},{"key":"40976_CR37","doi-asserted-by":"publisher","unstructured":"Tovar, M., Moreno, Y. & Sanz, J. Addressing mechanism bias in model-based impact forecasts of new tuberculosis vaccines. Zenodo repository: Bayesian_Framework_TB_Vaccines: Bayesian Framework for TB Vaccines analysis https:\/\/doi.org\/10.5281\/zenodo.8119663, (2023).","DOI":"10.5281\/zenodo.8119663,"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40976-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40976-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40976-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T17:30:10Z","timestamp":1700155810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40976-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40976"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-40976-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5312"}}